IART - Integra LifeSciences Still Underperforming As Manufacturing Issues Linger
2024-06-21 17:44:04 ET
Summary
- Integra LifeSciences Holdings Corporation has continued to disappoint, with the company missing its own timelines for the reopening of the Boston manufacturing facility (a key piece of the Tissue Technologies business).
- Management's guidance for the second half of 2024 may be too optimistic, particularly given legitimate concerns about the company's ability to deliver on operational execution.
- The acquisition of ACCLARENT is a ho-hum move with minimal synergy, but some potential for growth leverage in overseas markets.
- With the pending departure of the CEO, Integra could get a fresh start in 2025 and that is badly needed; the shares trade at a seemingly low price, but a lot of work lies ahead.
It’s really for the best that Seeking Alpha doesn’t offer any ASMR with its articles because the appropriate soundtrack for this part of the article for Integra LifeSciences Holdings Corporation (IART), where I often discuss the performance since my last article , would be the sounds of retching and dry heaving....
Integra LifeSciences Still Underperforming As Manufacturing Issues Linger